Study of Neutrophils During Gingival Inflammation in Children With Down Syndrome/Trisomy 21

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Since 2018, the Chicago Classification of Periodontal Diseases and Conditions, has listed Down syndrome (DS)/trisomy 21 (T21) as a systemic disease with periodontal implications. Numerous studies report an increased prevalence and severity of periodontitis in DS/T21 individuals under the age of 35. Approximately 35% of adolescents with DS show early signs of alveolar bone loss. However, very few studies have examined the role of immune deficiency in DS/T21 patients in the pathogenesis of periodontitis. Indeed, periodontitis induced by bacterial plaque is virtually non-existent in the paediatric population, leaving the field to systemically-induced periodontitis. The investigators hypothesize that specific neutrophil phenotypes in DS/T21 patients are key to explaining the rapid progression to periodontitis. Investigator's primary objective is to characterize the different oral and blood neutrophil subtypes in DS/T21 children with gingival inflammation. Investigator's secondary objective is to assess the involvement of different neutrophil subtypes in early periodontitis in children with DS/T21.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 3
Maximum Age: 12
Healthy Volunteers: f
View:

⁃ Common to all groups:

• Age: 3 to 12

• Patient affiliated to a social security program, beneficiary not covered by the AME.

• Legal representatives who speak and understand French well enough to be able to read and understand the study information.

• Legal representatives giving written consent for their child's participation in the study.

⁃ Specific:

⁃ Case Group:

• Trisomy 21 patient with gingival inflammation (subgroup 1)

• Trisomy 21 patient with healthy gingiva on intact periodontium with no history of periodontitis (subgroup 2)

⁃ Control Group: child meeting one of these criteria:

• Patient with psychomotor retardation with no known repercussions on the orofacial sphere or immunity, presenting gingival inflammation (subgroup 1)

• Patients with psychomotor retardation and no known repercussions on orofacial health or immunity, presenting gingival health on intact periodontium with no history of gingival inflammation (subgroup 2).

• Patients with no known general pathology and gingival inflammation (subgroup 3)

• Patients with no known general pathology and healthy gingiva on intact periodontium with no history of gingival inflammation (subgroup 4)

Locations
Other Locations
France
Carles-Foix Hospital
RECRUITING
Ivry-sur-seine
Contact Information
Primary
Marjolaine Ms GOSSET, PU-PH
marjolaine.gosset@aphp.fr; marjolaine.gosset@u-paris.fr
0149594811
Backup
Anne Laure Ms BONNET, MCU-PH
anne-laure.bonnet@aphp.fr
0149594811
Time Frame
Start Date: 2025-04-30
Estimated Completion Date: 2027-04-30
Participants
Target number of participants: 18
Treatments
Experimental: Child patient consulting the service
* Trisomy 21 patient with gingival inflammation (subgroup 1)~* Trisomy 21 patient with healthy gingiva on intact periodontium with no history of periodontitis (subgroup 2)~* Patient with psychomotor retardation with no known repercussions on the orofacial sphere or immunity, presenting gingival inflammation (subgroup 1)~* Patients with psychomotor retardation and no known repercussions on orofacial health or immunity, presenting gingival health on intact periodontium with no history of gingival inflammation (subgroup 2).~* Patients with no known general pathology and gingival inflammation (subgroup 3)~* Patients with no known general pathology and healthy gingiva on intact periodontium with no history of gingival inflammation (subgroup 4)
Related Therapeutic Areas
Sponsors
Leads: Assistance Publique - Hôpitaux de Paris

This content was sourced from clinicaltrials.gov

Similar Clinical Trials